PMID- 23911220 OWN - NLM STAT- MEDLINE DCOM- 20140414 LR - 20130909 IS - 1873-1244 (Electronic) IS - 0899-9007 (Linking) VI - 29 IP - 10 DP - 2013 Oct TI - Autism as a disorder of deficiency of brain-derived neurotrophic factor and altered metabolism of polyunsaturated fatty acids. PG - 1175-85 LID - S0899-9007(13)00054-3 [pii] LID - 10.1016/j.nut.2013.01.012 [doi] AB - Autism has a strong genetic and environmental basis in which inflammatory markers and factors concerned with synapse formation, nerve transmission, and information processing such as brain-derived neurotrophic factor (BDNF), polyunsaturated fatty acids (PUFAs): arachidonic (AA), eicosapentaenoic (EPA), and docosahexaenoic acids (DHA) and their products and neurotransmitters: dopamine, serotonin, acetylcholine, gamma-aminobutyric acid, and catecholamines and cytokines are altered. Antioxidants, vitamins, minerals, and trace elements are needed for the normal metabolism of neurotrophic factors, eicosanoids, and neurotransmitters, supporting reports of their alterations in autism. But, the exact relationship among these factors and their interaction with genes and proteins concerned with brain development and growth is not clear. It is suggested that maternal infections and inflammation and adverse events during intrauterine growth of the fetus could lead to alterations in the gene expression profile and proteomics that results in dysfunction of the neuronal function and neurotransmitters, alteration(s) in the metabolism of PUFAs and their metabolites resulting in excess production of proinflammatory eicosanoids and cytokines and a deficiency of anti-inflammatory cytokines and bioactive lipids that ultimately results in the development of autism. Based on these evidences, it is proposed that selective delivery of BDNF and methods designed to augment the production of anti-inflammatory cytokines and eicosanoids and PUFAs may prevent, arrest, or reverse the autism disease process. CI - Copyright (c) 2013 Elsevier Inc. All rights reserved. FAU - Das, Undurti N AU - Das UN AD - UND Life Sciences, Shaker Heights, OH, USA. Undurti@hotmail.com LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20130730 PL - United States TA - Nutrition JT - Nutrition (Burbank, Los Angeles County, Calif.) JID - 8802712 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0 (Catecholamines) RN - 0 (Cytokines) RN - 0 (Neurotransmitter Agents) RN - 25167-62-8 (Docosahexaenoic Acids) RN - 27YG812J1I (Arachidonic Acid) RN - 31C4KY9ESH (Nitric Oxide) RN - 333DO1RDJY (Serotonin) RN - 56-12-2 (gamma-Aminobutyric Acid) RN - AAN7QOV9EA (Eicosapentaenoic Acid) RN - N9YNS0M02X (Acetylcholine) RN - VTD58H1Z2X (Dopamine) SB - IM MH - Acetylcholine/metabolism MH - Anti-Inflammatory Agents/metabolism MH - Arachidonic Acid/*metabolism MH - Autistic Disorder/genetics/*metabolism/physiopathology/prevention & control MH - Brain-Derived Neurotrophic Factor/*deficiency/metabolism MH - Catecholamines/metabolism MH - Cytokines/deficiency/metabolism MH - Docosahexaenoic Acids/*metabolism MH - Dopamine/metabolism MH - Eicosapentaenoic Acid/*metabolism MH - Humans MH - Magnetic Resonance Imaging MH - Neurotransmitter Agents/metabolism MH - Nitric Oxide/metabolism MH - Serotonin/metabolism MH - gamma-Aminobutyric Acid/metabolism OTO - NOTNLM OT - Autism OT - Brain-derived neurotrophic factor OT - Cytokines OT - Inflammation OT - Lipoxins OT - Memory OT - Nitric oxide OT - Polyunsaturated fatty acids OT - Prostaglandins OT - Resolvins EDAT- 2013/08/06 06:00 MHDA- 2014/04/15 06:00 CRDT- 2013/08/06 06:00 PHST- 2012/10/29 00:00 [received] PHST- 2012/12/12 00:00 [revised] PHST- 2013/01/12 00:00 [accepted] PHST- 2013/08/06 06:00 [entrez] PHST- 2013/08/06 06:00 [pubmed] PHST- 2014/04/15 06:00 [medline] AID - S0899-9007(13)00054-3 [pii] AID - 10.1016/j.nut.2013.01.012 [doi] PST - ppublish SO - Nutrition. 2013 Oct;29(10):1175-85. doi: 10.1016/j.nut.2013.01.012. Epub 2013 Jul 30.